Mg Of Coenzyme Q10 Research Articles

Investigating the Effect of Coenzyme Q10 in the Treatment of Sudden Sensorineural Hearing Loss

Background and Objective: Sudden sensorineural hearing loss (SSNHL) is a complication that is usually unilateral and can be accompanied by tinnitus and vertigo. Although various infectious, vascular, and immune etiologies have been proposed for SSNHL, the cause is unknown in most cases. Therefore, this study aimed to determine the effect of coenzyme Q10 in the treatment of SSNHL. Materials and Methods: This study was a double-blind, randomized, controlled clinical trial, which was conducted using the available sampling method. A total of 60 patients with SSNHL (18-70 years old) lasting less than one month were divided into two groups: intervention and control. The routine treatment of both groups included weekly injections of dexamethasone in the middle ear for 3 weeks. The intervention group also received 100 mg of coenzyme Q10 per day for 4 weeks, while the control group received a placebo. Patients were evaluated by basic audiological tests at the baseline and third and sixth months after the treatment. Statistical analysis of findings was done in SPSS26 software. Results: The difference in the mean pure tone hearing thresholds of the intervention and control groups was significant in the third month (29.33±15.96 dB and 35.34±12.24 dB; P=0.02) and sixth month (dB 28.00±16.27 and dB 34.33±11.87; P=0.01). Conclusion: In patients with SSNHL, combined treatment with oral coenzyme Q10 at the rate of 100 mg per day, along with intratympanic injection of dexamethasone for four weeks, can improve pure tone hearing thresholds and facilitate the treatment

Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial

BackroundMetabolic-dysfunction Associated Steatotic Liver Disease (MASLD) has been associated with increased cardiovascular risk. The aim of this Randomized Double-blind clinical Trial was to evaluate the effects of coenzyme-Q10 supplementation in patients with MASLD in terms of endothelial, vascular and myocardial function.MethodsSixty patients with MASLD were randomized to receive daily 240 mg of coenzyme-Q10 or placebo. At baseline and at 6-months, the a)Perfused boundary region of sublingual vessels using the Sideview Darkfield imaging technique, b)pulse-wave-velocity, c)flow-mediated dilation of the brachial artery, d)left ventricular global longitudinal strain, e)coronary flow reserve of the left anterior descending coronary artery and f)controlled attenuation parameter for the quantification of liver steatosis were evaluated.ResultsSix months post-treatment, patients under coenzyme-Q10 showed reduced Perfused boundary region (2.18 ± 0.23vs.2.29 ± 0.18 μm), pulse-wave-velocity (9.5 ± 2vs.10.2 ± 2.3 m/s), controlled attenuation parameter (280.9 ± 33.4vs.304.8 ± 37.4dB/m), and increased flow-mediated dilation (6.1 ± 3.8vs.4.3 ± 2.8%), global longitudinal strain (-19.6 ± 1.6vs.-18.8 ± 1.9%) and coronary flow reserve (3.1 ± 0.4vs.2.8 ± 0.4) compared to baseline (p < 0.05). The placebo group exhibited no improvement during the 6-month follow-up period (p > 0.05). In patients under coenzyme-Q10, the reduction in controlled attenuation parameter score was positively related to the reduction in Perfused boundary region and pulse wave velocity and reversely related to the increase in coronary flow reserve and flow-mediated dilation (p < 0.05 for all relations).ConclusionsSix-month treatment with high-dose coenzyme-Q10 reduces liver steatosis and improves endothelial, vascular and left ventricle myocardial function in patients with MASLD, demonstrating significant improvements in micro- and macro-vasculature function.Trial RegistrationNCT05941910

Formulation Development and Evaluation of Ubidecarenone Chewable Tablet

Background: Coenzyme Q10 has a role in mitochondrial transport system and can be utilized as a supplement in migraine prevention. This study's objective is to assess Coenzyme Q10's effectiveness when used in conjunction with conventional medications to prevent migraines. Adding 300mg of coenzyme Q10 each day to prescription medications, while another group of patients continued receiving standard care. Over the course of a three-month treatment period, data on attack frequency, headache pain intensity, monthly migraine days, and associated symptoms like nausea, vomiting, phonophobia, and photophobia were analyses. Ubidecarenone, a medicinal component. The goal is to produce Ubidecarenone in a 300 mg chew-able tablet form. In vitro release studies and organoleptic properties, such as taste and flavour, will be evaluated. investigations in the early stages, tests for medicine excipient compatibility, and analyses of the water content Quality Assurance for the Process Hausner's Ratio, Bulk Density, Tapped Density, Comprehensibility Index, and Angle of Repose for calculating derived properties for medications and mixtures. ingredients that have been optimised for their concentrations, such as tastes, sweeteners, disintegrants, wetting agents, glidants, and lubricants. putting the best possible ingredients together to make a chew able pill. Evaluation of chewable tablets for post compression parameters including uniformity of weight, thickness, hardness, brittleness, friability, dissolution, assay, and in vitro drug release properties. An evaluation of the optimised batch's palatability is required. The intention is to create chewable tablets of ubidecarenone. Method: The wet granulation method is used to make chewable tablets of ubidecarenone. Mannitol is used as a diluent, crospovidone as a disintegrant agent, sodium starch as a disintegrate agent, saccharin sodium as a sucrose sweetener, orange flavour, peppermint oil as a flouring agent, and colloidal silicon dioxide as a gliding. The Ubidecarenone (300 mg) is one of the best first-line treatments for migraine prevention.

Mitochondrial disorders in patients with familial form of MERRF syndrome

MERRF syndrome (myoclonic epilepsy ragged red fibres) belongs to the group of primary mitochondrial diseases and is characterized by a combination of myoclonic epilepsy and the phenomenon of ragged red fibres on muscle biopsy. The aim of this work is to study mitochondrial disorders in patients from a family with MERRF syndrome by determining the cytochemical activity of mitochondrial enzymes in peripheral blood lymphocytes and the level of lactate in the blood. Clinical cases of a 25-year-old sister and a 19-year-old brother with MERRF syndrome with the m.8344A&gt;G variant in MT-TK (tRNA (Lys)) with a blood heteroplasmy level of 50 % in the sister and homoplasmy in the brother are presented. Mitochondrial disorders were assessed by blood lactate levels and cytochemical studies of mitochondrial enzyme activity in peripheral blood lymphocytes. Pre-prandial blood lactate levels were elevated in both patients. After a carbohydrate load, it increased in the sister, and decreased in the brother. The sister had decreased activity of peripheral blood lymphocyte enzymes while taking levetiracetam, 100 mg of coenzyme Q10 and 100 mg of L-carnitine. The dose of energotropic drugs was increased, which led to an increase in the activity of mitochondrial enzymes. The brother had a compensatory increase in the level of succinate dehydrogenase and a decrease in the activity of other enzymes. The methods we used can be used in clinical practice to diagnose mitochondrial disorders and to adjust the dosage of energotropic drugs, which remain relevant due to the lack of effective gene therapy.

The Role and Place of Antioxidants in the Treatment of Male Infertility Caused by Varicocele.

The inability to become pregnant for at least 1 year despite regular unprotected intercourse may indicate infertility of one or both partners. This problem affects approximately 10-20% of couples worldwide, regardless of race, with male infertility reported to account for 25-60% of cases. Among the most common pathological causes of male infertility is the presence of varicocele and chronic infections of the male reproductive system. This study was performed using data collected at the Genesis Infertility Treatment Clinic, Bydgoszcz, Poland, between 1 January 2015 and 30 June 2017. A total of 163 men meeting the inclusion criteria were selected and divided into the idiopathic infertility group (78 men) and varicocele-related infertility group (85 men). All patients received treatment with a male fertility supplement containing a combination of 1725 mg of L-carnitine fumarate, 500 mg of acetyl-L-carnitine, 90 mg of vitamin C, 20 mg of coenzyme Q10, 10 mg of zinc, 200 µg of folic acid, 50 µg of selenium, and 1.5 µg of vitamin B12 (Proxeed® Plus, Sigma-Tau, Italy) twice a day for a period of 6 months from the time of the diagnosis of infertility. The treatment resulted in significant improvements in general semen parameters, particularly sperm count, sperm concentration, total motility, and progressive motility. This antioxidant therapy produced a particularly marked therapeutic benefit in patients with Grade III varicocele, with a greater improvement in progressive motility than in men with less severe or no varicocele. The use of the antioxidant preparation examined here seems reasonable in men with idiopathic infertility and as an adjuvant in those with varicocele-related infertility in whom surgical treatment has resulted in no improvement. Its use should be considered particularly in patients with Grade III varicocele who do not wish to undergo surgical treatment or in whom such a treatment is not possible for various reasons.

Royal Jelly Plus Coenzyme Q10 Supplementation Enhances High-Intensity Interval Exercise Performance via Alterations in Cardiac Autonomic Regulation and Blood Lactate Concentration in Runners.

PurposeThis study aimed to examine whether oral royal jelly (RJ) and coenzyme Q10 (CoQ10) co-supplementation could improve high-intensity interval exercise (HIIE) performance in runners, reducing exercise-induced lactic acidosis and decreasing elevated sympathetic tone following exercise.MethodsThirty regional-level runners (age: 19 ± 1 years; height: 173 ± 2 cm; body mass: 68.9 ± 2 kg; body mass index: 23.1 ± 1 kg/m2) were randomly allocated to receive either 400 mg of RJ and 60 mg of CoQ10 (RJQ) or matching placebo (PLA) once daily for 10 days. Exercise performance expressed as time taken to complete HIIE was evaluated at baseline, and then reassessed at day 10 of intervention. HIIE protocol applied to the runners included three repetitions of 100 m distance at maximum possible speed interspersed with 45 s of recovery periods. Indices of heart rate variability and blood lactate concentration were also measured before and immediately after HIIE in each group.ResultsHIIE performance significantly improved in RJQ group (p = 0.005) compared to PLA group. Blood lactate levels and sympathetic influence on the heart were significantly lower both before and after the HIIE in athletes who received RJQ (p < 0.05) compared to PLA. Regression analysis showed that oral RJQ administration for 10 days was significantly associated with reductions in HIIE-induced increases in blood lactate concentration and enhanced cardiac parasympathetic modulation following exercise compared to PLA. Principal component analysis revealed that runners treated with RJQ are grouped by the first two principal components into a separate cluster compared to PLA. Correlation analysis demonstrated that the improvements in runners’ HIIE performance were due in significant part to RJQ-induced reduction of increment in blood lactate levels in response to exercise in combination with a more rapid shift in autonomic activity toward increased parasympathetic control early at post-exercise.ConclusionThese findings suggest that RJQ supplementation for 10 days is potentially effective for enhancing HIIE performance and alleviating adverse effects of increased intramuscular acidity and prolonged sympathetic dominance following intense exercise.

Royal jelly plus coenzyme Q10 supplementation improves high-intensity interval exercise performance via changes in plasmatic and salivary biomarkers of oxidative stress and muscle damage in swimmers: a randomized, double-blind, placebo-controlled pilot trial.

ABSTRACTBackgroundExcessive production of free radicals caused by many types of exercise results in oxidative stress, which leads to muscle damage, fatigue, and impaired performance. Supplementation with royal jelly (RJ) or coenzyme Q10 (CoQ10) has been shown to attenuate exercise-induced oxidant stress in damaged muscle and improve various aspects of exercise performance in many but not all studies. Nevertheless, the effects of treatments based on RJ plus CoQ10 supplementation, which may be potentially beneficial for reducing oxidative stress and enhancing athletic performance, remain unexplored. This study aimed to examine whether oral RJ and CoQ10 co-supplementation could improve high-intensity interval exercise (HIIE) performance in swimmers, inhibiting exercise-induced oxidative stress and muscle damage.MethodsTwenty high-level swimmers were randomly allocated to receive either 400 mg of RJ and 60 mg of CoQ10 (RJQ) or matching placebo (PLA) once daily for 10 days. Exercise performance was evaluated at baseline, and then reassessed at day 10 of intervention, using a HIIE protocol. Diene conjugates (DC), Schiff bases (SB), and creatine kinase (CK) were also measured in blood plasma and saliva before and immediately after HIIE in both groups.ResultsHIIE performance expressed as number of points according to a single assessment system developed and approved by the International Swimming Federation (FINA points) significantly improved in RJQ group (p = 0.013) compared to PLA group. Exercise-induced increase in DC, SB, and CK levels in plasma and saliva significantly diminished only in RJQ group (p < 0.05). Regression analysis showed that oral RJQ administration for 10 days was significantly associated with reductions in HIIE-induced increases in plasmatic and salivary DC, SB, and CK levels compared to PLA. Principal component analysis revealed that swimmers treated with RJQ are grouped by both plasmatic and salivary principal components (PC) into a separate cluster compared to PLA. Strong negative correlation between the number of FINA points and plasmatic and salivary PC1 values was observed in both intervention groups.ConclusionThe improvements in swimmers’ HIIE performance were due in significant part to RJQ-induced reducing in lipid peroxidation and muscle damage in response to exercise. These findings suggest that RJQ supplementation for 10 days is potentially effective for enhancing HIIE performance and alleviating oxidant stress.AbbreviationsRJ, royal jelly; CoQ10, coenzyme Q10; HIIE, high-intensity interval exercise; DC, diene conjugates; SB, Schiff bases; CK, creatine kinase; RJQ, royal jelly plus coenzyme Q10; PLA, placebo; FINA points, points according to a single assessment system developed and approved by the International Swimming Federation; ROS, reactive oxygen species; 10H2DA, 10-hydroxy-2-decenoic acid; AMPK, 5′-AMP-activated protein kinase; FoxO3, forkhead box O3; MnSOD, manganese-superoxide dismutase; CAT, catalase; E, optical densities; PCA, principal component analysis; PC, principal component; MCFAs, medium-chain fatty acids; CaMKKβ, Ca2+/calmodulin-dependent protein kinase β; TBARS, thiobarbituric acid reactive substances; MDA, malondialdehyde.

Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk

ObjectiveThe use of nutritional supplements to treat hypercholesterolemia is gradually increasing, however further studies on their efficacy and safety are required. Patients and methodsThe present clinical trial included patients with moderate hypercholesterolemia and cardiovascular risk who were treated either with a nutraceutical preparation containing 3.75mg of monacolin K, 515mg of berberine and 50mg of coenzyme Q10 per tablet (Lipok®) or with a placebo. The clinical and laboratory variables were analyzed at baseline and at three and six months. None of the patients was diabetic, and none was being treated with lipid-lowering drugs or with any other nutritional supplements affecting lipid metabolism. ResultsIn patients of the intervention group and of the placebo group, baseline LDL-C was 134.7mg/dL (14.4) and 138.7mg/dL (15.2), respectively. At three months after treatment start, LDL-C had decreased by 26.1mg/dL (−32.4 to 19.7) and increased by 4.5mg/dL (−1.5 to 10.5) in the respective groups. In the intervention group, a similar decrease in non-HDL-C and total cholesterol was observed, while no significant changes were observed in either group for HDL-C, triglycerides and lipoprotein(a). A good tolerance and safety profile was observed. ConclusionIn conclusion, this study demonstrates that the combination of monacolin K, berberine and coenzyme Q10 is effective and safe for treating hypercholesterolemia in patients with a moderate degree of excess LDL-C and cardiovascular risk.

Does Coenzyme Q10 Plus Selenium Supplementation Ameliorate Clinical Outcomes by Modulating Oxidative Stress and Inflammation in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a neuroinflammatory, multifaceted chronic disorder of unknown cause. Accumulating data indicate a link between a redox imbalance, mitochondrial dysfunction, and inflammation status in ME/CFS. Coenzyme Q10 (CoQ10) and selenium as effective antioxidant and anti-inflammatory agents have shown potential clinical implications in chronic diseases; however, their therapeutic benefits in ME/CFS remain elusive. This open-label exploratory study aimed to evaluate the effectiveness of combined CoQ10 plus selenium supplementation on clinical features and circulating biomarkers in ME/CFS. Twenty-seven ME/CFS patients received an oral combination of 400 mg of CoQ10 and 200 μg of selenium daily for 8 weeks. The primary endpoint was patient-reported changes in outcome measures from baseline to 8 weeks' postintervention. Secondary endpoint included changes in circulating biomarkers from baseline to each participant. After an 8-week intervention, a significant improvement was found for overall fatigue severity (p = 0.021) and global quality of life (p = 0.002), while there was no significant effect on the sleep disturbances (p = 0.480) among participants. After 8 week's intervention, there was significantly increased total antioxidant capacity, and there were reduced lipoperoxide levels from the participants (p < 0.0001 for both). Circulating cytokine levels decreased significantly (p < 0.01 for all), but with no significant changes in the C-reactive protein, FGF21, and NT-proBNP biomarkers after supplementation. Based on these findings, we hypothesized that long-term supplementation of combined CoQ10 and selenium may indicate a potentially beneficial synergistic effect in ME/CFS. Antioxid. Redox Signal. 36, 729–739.

Antioxidants Effect Changes in Systemic Parasympathetic and Sympathetic Nervous System Responses and Improve Outcomes

Parasympathetic and Sympathetic (P&amp;S) imbalance is associated with increased morbidity and mortality risk, including heart failure, coronary artery disease, atrial and ventricular arrhythmias, hypertension and orthostatic disorders, and syncope. Most cardiac medications effect only one or the other of the P&amp;S nervous systems, including: β-blockers, α-blockers, α-agonists, and anti-cholinergics. Non-pharmaceutical treatments also affect the P&amp;S nervous systems; however, nonpharmaceutical treatment is rarely addressed or studied, despite significant evidence-based data demonstrating normalization of Sympathovagal Balance. Fifty consecutive patients from a busy suburban cardiology practice were enrolled in a supplement study. Patients were provided supplements that included 200mg of Alpha-Lipoic Acid (ALA) and 100mg of Co-Enzyme Q10 (CoQ10) which they were instructed to take twice a day, one each with breakfast and dinner. P&amp;S Monitoring (Physio PS, Inc., Atlanta, GA, USA) and Quality of Life (QoL) questionnaires were administered at three month intervals. The combination of supplements, ALA and CoQ10, had a positive effect on the P&amp;S nervous systems as measured directly and also indicated by improvements in BP, HR and reported QoL. The study indicates these supplements help to improve both the resting and challenge P&amp;S responses and resultant physiology. The results suggest antioxidant therapy is a potential complimentary therapy to pharmacological management of patients with poorly controlled BP (i.e., hypertension and possible hypotension) as well as in patients with tachycardia or palpitations. This is a hypothesis generating study of significant importance in an often neglected area of cardiovascular disease in which additional research and studies are needed.

Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals

Coenzyme Q10 (CoQ10) plays a central role in mitochondrial oxidative phosphorylation. Several studies have shown the beneficial effects of dietary CoQ10 supplementation, particularly in relation to cardiovascular health. CoQ10 biosynthesis decreases in the elderly, and consequently, the beneficial effects of dietary supplementation in this population are of greater significance. However, most pharmacokinetic studies have been conducted on younger populations. The aim of this study was to investigate the single-dose bioavailability of different formulations of CoQ10 in a healthy geriatric population. A randomized, three-period, crossover bioavailability study was conducted on 21 healthy older adults (aged 65–74). The treatment was a single dose with a one-week washout period. Three different formulations containing the equivalent of 100 mg of CoQ10 were used: Q10Vital® water-soluble CoQ10 syrup (the investigational product—IP); ubiquinol capsules (the comparative product—CP); and ubiquinone capsules (the standard product—SP). Ubiquinone/ubiquinol was followed in the plasma for 48 h. An analysis of the ratio of the area under the baseline-corrected concentration curve (ΔAUC48) for total CoQ10 and a comparison to SP yielded the following: The bioavailability of CoQ10 in the IP was 2.4-fold higher (95% CI: 1.3–4.5; p = 0.002), while the bioavailability of ubiquinol (CP) was not significantly increased (1.7-fold; 95% CI: 0.9–3.1, p = 0.129). No differences in the redox status of the absorbed coenzyme Q10 were observed between formulations, showing that CoQ10 appeared in the blood mostly as ubiquinol, even if consumed as ubiquinone.

Coenzyme Q10 administration has no effect on sICAM-1 and metabolic parameters of pediatrics with type 1 diabetes mellitus.

Background: Endothelial dysfunction (ED) plays a key role in the development and progression of microvascular and macrovascular complications in pediatrics with type 1 diabetes mellitus (T1DM). Coenzyme Q10 (CoQ10) is a nutraceutical with a known anti-inflammatory and anti-oxidant activity. This study was conducted to evaluate the potential effect of CoQ10 on ED and various metabolic parameters. Methods: This prospective randomized open-label pilot study was conducted on 49 T1DM pediatric patients. Seven healthy non-diabetic pediatric subjects who didn't receive treatment were included as a control group. Eligible patients were randomly allocated into either group I (n=25); received 100mg of CoQ10 in addition to standard treatment or group II (n=24); received standard treatment only. The levels of; soluble intracellular adhesion molecule-1 (sICAM-1), glycated hemoglobin (HbA1c), fasting blood glucose (FBG), lipid profile, serum creatinine and liver function tests were assessed for both groups at baseline and after 3 months of treatment. Results: At baseline, compared to an age-matched healthy control group sICAM-1 levels were significantly elevated in group II diabetic patients (276.5 (231.6-320.66) vs 221.8 (177.9-267.1ng/ml), p=0.042. After 3 months of treatment no significant difference was observed in sICAM-1, HbA1c, FBG, lipid profile, serum creatinine and liver function tests between the two study groups. A positive correlation was found between sICAM-1 and HbA1c throughout the study (r=0.308, p=0.0054). Conclusion: Administration of CoQ10 for 3 months in T1DM pediatric patients was well tolerated but had no favorable effect on ED or metabolic parameters.

Effect of antioxidant supplementation containing L-carnitine on semen parameters: a prospective interventional study.

Objective:One of the remarkable causes of infertility in men is oxidative stress having a reducing effect on their reproductive function. In the present study, we investigated the efficacy of supplementation with antioxidants and L-Carnitine (contained in Androferti) on semen parameters.Methods:We included 180 infertile male patients diagnosed with idiopathic oligoastenoteratozoospermia (OAT) in this study, and we analyzed the semen sample from 59 patients before and after oral antioxidant treatment, with the commercial name of Androferti (containing 1500 mg of L-Carnitine, 60 mg of vitamin C, 20 mg of coenzyme Q10, 10 mg of vitamin E, 10 mg of zinc, 200 µg of vitamin B9, 50 µg of selenium, 1 µg of vitamin B12). All of the patients received Androferti twice a day for 3 months. Results:There were significant improvements in the sperm concentration (p=0.004) after the antioxidant supplementation. There was also a meaningfully improvement in sperm morphology (p=0.01) after treatment. However, sperm motility was not significantly altered after antioxidant treatment (p=0.2).Conclusions:Antioxidants supplementation containing 1500 mg L-carnitine can improve the semen quality in infertile men diagnosed with idiopathic OAT. However, further studies are required to determine the antioxidant effects on reproduction function.

Coenzyme Q10 supplementation effects on lipid ratios in women with type 2 diabetes mellitus: A randomized, double-blind clinical trial study

Objective: This study had been designed to evaluate the effects of Coenzyme Q10 (CoQ10) supplementation on the lipid ratios in women with type 2 diabetes mellitus (T2DM).&#x0D; Materials and Methods: Sixty-eight women with T2DM were enrolled and randomly divided into two groups. While one group received 100 mg/day of CoQ10 supplement for 12 weeks (n=34) the other was given placebo for the same time duration (n=34). Lipid profile including triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were evaluated at the beginning and at the end of the intervention and lipid ratios were calculated.&#x0D; Results and Discussion: After the intervention, values of non-HDL-C (p=0.001), TG/HDL-C (p=0.03) and LDL-C/HDL-C (p=0.001) were significantly decreased in CoQ10 group. Values of HDL ratio (p=0.002) were increased significantly in CoQ10 group.&#x0D; Conclusion: This study showed that daily supplementation with 100 mg of CoQ10 in women with T2DM could improve some atherogenic lipid ratios that might be useful in preventing cardiovascular diseases in them.&#x0D; Bangladesh Journal of Medical Science Vol.19(1) 2020 p.152-158

EFFECTIVENESS AND SAFETY OF A NEW GENERATION OF NUTRACEUTICAL COMPOUNDS ON LIPID PROFILE AND SERUM GLYCAEMIA IN SUBJECTS WITH HIGH-NORMAL BLOOD PRESSURE LEVELS

Objective: In the 2018 ESH/ESC hypertension guidelines is recommend that patients with high–normal blood pressure (BP) values and low–moderate cardiovascular (CV) risk should be offered lifestyle advice, because this reduces their risk of progressing to established hypertension and may further reduce their CV risk. Treatment strategies include non-pharmacologic interventions and in this respect a relevant role has been shown for nutraceutical compounds (NCs). Design and method: 131 subjects (mean age 55.7 ± 9.6 years, 53% males) with high-normal BP levels (i.e. with systolic BP of 130–139 mmHg and/or with diastolic BP of 85–89 values) without hypertension-mediated organ damage and history of cardio-vascular (CV) diseases were enrolled. 66 subjects were treated with a once-daily oral formulation of a NCs containing red yeast rice (equivalent of 3 mg of Monacolin K), 500 mg of Berberine, 30 mg of Coenzyme Q10, 200 mcg of folic acid and 40 mg of chrome that added to their diet for 3 months and were compared with the 65 patients following a diet program. Differences in serum total cholesterol (TC), low- and high-density-lipo- protein cholesterol (LDLC and HDLC), triglycerides (TG), glucose values, CPK, AST, ALT and BMI were compared by analysis of variance. Results: A significant reduction of TC, LDLC and glucose levels was observed in both treatment groups, while HDLC values significantly increased in the active treatment group (+4.8 %, p < 0.0001). However, a greater reduction of TC (-13.6%) LDLC (-17.7%), and serum glucose (-7.7%) was observed in the treatment group that to the control (p < 0.001 for all). BP, BMI and TG levels remained unchanged (p = N.S.). Gender difference was not found in either group (p = N.S.). No adverse event was observed during the study and safety parameters (i.e AST, ALT and CPK values) was not-different between groups; 2 subjects in the active and 2 in the control group withdrew from the study. Conclusions: In patients with high-normal BP levels, NC supplementation was safe, well tolerated and effective in improving lipid pattern and glucose profile.

Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization.

Bioavailability of supplements with coenzyme Q10 (CoQ10) in humans seems to depend on the excipients of formulations and on physiological characteristics of the individuals. The aim of this study was to determine which factors presented in CoQ10 supplements affect the different response to CoQ10 in humans. We tested seven different supplement formulations containing 100 mg of CoQ10 in 14 young, healthy individuals. Bioavailability was measured as area under the curve of plasma CoQ10 levels over 48 h after ingestion of a single dose. Measurements were repeated in the same group of 14 volunteers in a double-blind crossover design with a minimum of 4 wk washout between intakes. Bioavailability of the formulations showed large differences that were statistically significant. The two best absorbable formulations were soft-gel capsules containing ubiquinone (oxidized CoQ10) or ubiquinol (reduced CoQ10). The matrix used to dissolve CoQ10 and the proportion and addition of preservatives such as vitamin C affected the bioavailability of CoQ10. Although control measurements documented that all formulations contained 100 mg of either CoQ10 or ubiquinol, some of the participants showed high and others lower capacity to reach high increase of CoQ10 in blood, indicating the participation of individual unknown physiological factors. This study highlights the importance of individually adapted selection of best formulations to reach the highest bioavailability of CoQ10 in humans.

Effects of coenzyme Q10 supplementation on the serum levels of amylase, adenosine deaminase, catalase, and total antioxidant capacity in women with type 2 diabetes mellitus: A randomized, double-blind placebo-controlled trial.

Background:Increased levels of reactive oxygen species is a key factor involved in the pathogenesis of type 2 diabetes mellitus (T2DM). Coenzyme Q10 (CoQ10) is a nonenzymatic antioxidant that restores other antioxidants.Materials and Methods:This randomized, double-blind placebo-controlled trial study has been designed to evaluate the effects of CoQ10 supplementation on serum values of amylase, adenosine deaminase, catalase (CAT), total antioxidant capacity (TAC) and the quantitative insulin sensitivity check index (QUICKI) in women with T2DM. Serum levels of CoQ10 were measured too. Sixty-eight women with T2DM were enrolled in this study and randomly divided into two groups. One group received 100 mg/day of CoQ10 supplement for 12 weeks (n = 34), and the other group was given placebo for the same time duration and dosage (n = 34).Results:After the intervention, serum CAT activity (P < 0.001), TAC (P = 0.006), CoQ10 (P = 0.001), and QUICKI (P = 0.005) increased and fasting blood sugar (FBS) (P = 0.05) decreased significantly in CoQ10 group.Conclusion:This study showed that daily supplementation with 100 mg of CoQ10 could increase TAC and CAT activity as, CoQ10 and QUICKI and could reduce oxidative stress and FBS in women with T2DM.

The effect of dietary intake of coenzyme Q10 on skin parameters and condition: Results of a randomised, placebo‐controlled, double‐blind study

Coenzyme Q10 (CoQ10) is a natural constituent of foods and is also often used in both functional foods and supplements. In addition, it is a common ingredient of cosmetics where it is believed to reduce the signs of skin ageing. However, the existing data about the effect of dietary intake of CoQ10 on skin parameters and condition are scarce. To gain an insight into this issue, we conducted a double-blind, placebo-controlled experiment with 33 healthy subjects. Our objective was to investigate the effects of 12weeks of daily supplementation with 50 and 150mg of CoQ10 on skin parameters and condition. Study was conducted with a water-soluble form of CoQ10 with superior bioavailability (Q10Vital® ). While the results of some previous in vitro studies showed possible protection in UVB response, we did not observe significant changes in the minimal erythema dose (MED). On the other hand, the intake of CoQ10 limited seasonal deterioration of viscoelasticity and reduced some visible signs of ageing. We determined significantly reduced wrinkles and microrelief lines, and improved skin smoothness. Supplementation with CoQ10 did not significantly affect skin hydration and dermis thickness. © 2016 BioFactors, 43(1):132-140, 2017.

Role of Coenzyme Q10 in Breast Cancer

Background: Coenzyme Q10 (CoQ10) is a biological quinone compound that has two major physiological activities, as an antioxidant and as a redox component in the respiratory chain. Those CoQ10 activities among others may be of importance for the prognosis and treatment of breast cancer, which is the most commonly diagnosed cancer among women. Objective: The purpose of this study was to conduct a literature review to identify and assess the evidence of the effect of CoQ10 for the treatment of breast cancer as a supplement, and to establish the relationship between CoQ10 levels and breast cancer. Methods: In order to better understand the role of this coenzyme in breast cancer, an electronic literature search was conducted to identify all studies in which coenzyme Q10 was administered or measured in breast cancer patients. Results: Six studies were included in this literature review. A relationship between CoQ10 levels and the risk of breast cancer was established. In those studies where patients were supplemented with a daily dose of 100mg of CoQ10, resulted in increased antioxidant levels, decreased cytokines plasma levels and reduced cancer biomarkers. Discussion: CoQ10 acts as antioxidant in lipid peroxidation, helps regenerate antioxidant enzymes and decreases inflammation markers that contribute to proliferation, metastasis, cancer cell survival and angiogenesis. Conclusion: The effectiveness of CoQ10 administration to improve the tolerability or prognosis of cancer treatments has not been fully evaluated and larger randomized clinical trials are needed to determine the optimum dose of CoQ10. However, the recommendation about the use of CoQ10 should not be considered as poor medicine practice, considering that it is safe, and the studies described in this review have some trends that favor the use of this supplement.

A Case Control Study of Melatonin with or Without Coenzyme Q10 in Improving Oocyte Quality and Outcomes in In vitro Fertilization

Antioxidant therapy is thought to improve oocyte quality through the reduction of oxidative stress. Melatonin and coenzyme Q10 (CoQ10) are known antioxidants. We aimed to investigate the clinical efficacy of exogenous melatonin supplementation with or without CoQ10 in improving oocyte quantity and quality. Fifty-three women undergoing cycles at Monash IVF were supplemented with melatonin 4 mg daily, with 19 of those additionally supplemented with 150 mg of CoQ10. Controls were matched at a 2:1 ratio to cases. Data were taken from an index (pretherapy) cycle and from a therapeutic (posttherapy) cycle for both cases and controls. Comparisons were made directly between cases and controls in the therapeutic cycle and by comparing the median differences of the change in outcomes from the index to therapeutic cycle. Primary outcomes included follicle, oocyte, and metaphase II oocytes (MII) counts. Results showed higher median absolute oocyte numbers (6.00 vs. 4.00, P = 0.049) in the case group. Cases and controls were significantly different when comparing median change between cycles in oocyte number (0.00 vs. -1.00, P = 0.028) and MII count (0.00 vs. -1.00, P = 0.034). However, this was the result of poorer outcomes in the control group rather than improvements in the case group, and it cannot be concluded that treatment improved oocyte quality.